Firsocostat

DB16166InvestigationalSmall molecule

Firsocostat is under investigation in clinical trial NCT02781584 (Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)).

Mechanism: Pharmacologically active on Acetyl-CoA carboxylase 1 and Acetyl-CoA carboxylase 2
Curator reviewed
Formula / weight: C₂₈H₃₁N₃O₈S · 569.63 g/mol (avg)
Code names: GS-0976 · GS-ACC · ND-630 · NDI-010976

Resolves to

Compound

UNIIXE10NJQ95MCAS1434635-54-7ChEMBLCHEMBL3407547

Structure

InChIKeyZZWWXIBKLBMSCS-FQEVSTJZSA-NSMILESCOC1=CC=CC=C1[C@H](CN1C2=C(C(C)=C(S2)C2=NC=CO2)C(=O)N(C1=O)C(C)(C)C(O)=O)OC1CCOCC1

Targets

Q13085ACACAO00763ACACB

Transporters

Q9Y6L6SLCO1B1P46721SLCO1A2Q9NPD5SLCO1B3

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3TransportersSubstrate / inhibitor direction, not just membership

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Firsocostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In